Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dapsone 5% Gel
Dapsone 5% · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Dapsone Topical Gel + adapalene gel 0.1% | DRUG | - |
| Dapsone Topical Gel + benzoyl peroxide gel 4% | DRUG | - |
| Dapsone Topical Gel + vehicle control | DRUG | - |
Inclusion Criteria: Study subjects will be considered for participation based upon medical history and findings from the pre-study interview and examination. They will be enrolled according to the following conditions: 1. Each subject or parent/guardian will read and sign the informed assent and/o...
Dapsone 5% is a topical small molecule treatment being developed for acne vulgaris. It is applied to the skin and has been studied in a Phase 3 trial in patients aged 12 years and older. The trial evaluated its use both as a standalone gel and in combination with adapalene gel 0.1% or benzoyl peroxide gel 4%.
Dapsone 5% is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the company responsible for the clinical development of this topical acne treatment.
Dapsone 5% is in Phase 3 clinical development for acne vulgaris. One Phase 3 trial has been completed, and no active trials are currently listed. The completed trial enrolled 301 participants and was randomized and double-blind.
Dapsone 5% has been studied in one completed Phase 3 trial, NCT00151541. This trial compared 5% dapsone topical gel twice daily in combination with a once-daily vehicle control, adapalene gel 0.1%, or benzoyl peroxide gel 4% in 301 participants with acne vulgaris.